智通财经APP获悉,中金发布研究报告称,上调药明生物(02269)目标价15%至19.09港元,维持“跑赢行业”评级。维持2024和2025年盈利预测不变,并首次引入2026年盈利预测46.93亿元人民币。药明生物发公告,爱尔兰疫苗工厂与默沙东(MSD International GmbH)达成协议,默沙东将收购药明海德在爱尔兰的疫苗工厂,总交易金额约5亿美元。公司预计本次交易将在20265年...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.